GWM
ONC

Geneos Wealth Management’s BeOne Medicines Ltd ONC Stock Holding History

Geneos Wealth Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$570 Hold
2
– – ﹤0.01% 2466
2026
Q1 		$594 Hold
2
– – ﹤0.01% 2455
2025
Q4 		$608 Hold
2
– – ﹤0.01% 2445
2025
Q3 		$681 Sell
2
-2
-50% -$607 ﹤0.01% 2438
2025
Q2 		$968 Buy
4
+2
+100% +$490 ﹤0.01% 2992
2025
Q1 		$544 Sell
2
-1
-33% -$234 ﹤0.01% 3036
2024
Q4 		$554 Buy
+3
New +$613 ﹤0.01% 2872

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geneos Wealth Management's ONC Position: Q2 2026 in Review

Geneos Wealth Management held its BeOne Medicines Ltd (ONC) position steady in Q2 2026 at 2 shares worth $570. The position accounts for ﹤0.01% of the portfolio, ranked #2466.

Geneos Wealth Management first reported a position in ONC in Q4 2024 and has held it in 7 quarters since. The position peaked at $968 in Q2 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Geneos Wealth Management held 2 shares of BeOne Medicines Ltd worth $570 as of Q2 2026.
  • Geneos Wealth Management left its BeOne Medicines Ltd share count unchanged in Q2 2026.
  • BeOne Medicines Ltd made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #2466 holding.
  • Geneos Wealth Management first reported a position in BeOne Medicines Ltd in Q4 2024 and has held it in 7 quarters since.
  • Geneos Wealth Management's BeOne Medicines Ltd position peaked at $968 in Q2 2025.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.